Advertisement

Journal of Neuro-Oncology

, Volume 110, Issue 1, pp 145–152 | Cite as

Conditional survival of high-grade glioma in Los Angeles County during the year 1990–2000

  • Denice D. Tsao-Wei
  • Jia Hu
  • Susan G. Groshen
  • Marc C. ChamberlainEmail author
Clinical Study

Abstract

Survival probabilities for high-grade glioma are estimated at the time of diagnosis and provide limited information following treatment. This study determined dynamic indices to predict post-diagnosis survival for high-grade glioma patients. Survival information for 2,743 patients with high-grade glioma, diagnosed in Los Angeles County during the years 1990–2000, were used to estimate conditional survival probabilities with 95 % confidence intervals, for patients still alive at 1, 2, 3, 4, or 5 years after diagnosis. The conditional probabilities of surviving one additional year increase as the post-diagnosis survival time increases (from 43 ± 2 % conditional on surviving 1 year after diagnosis to 91 ± 2 % conditional on surviving 5 years after diagnosis). Patients diagnosed with WHO grade III gliomas have higher conditional survival probabilities than those diagnosed WHO grade IV gliomas. However, as the years after diagnosis increase, the differences in the conditional probabilities between the two groups are attenuated. At the time of diagnosis, age and tumor histology (WHO grade), tumor site, primary treatment, time of treatment start after diagnosis, as well as whether the patient was treated at a teaching hospital were significantly associated with overall survival. By 4 years post-diagnosis however, with the exception of age, variables associated with survival at baseline were no longer significantly associated with survival. Conditional survival probabilities provide clinically relevant information for understanding the prognosis for patients with high-grade gliomas.

Keywords

Conditional survival High-grade glioma Los Angeles County 

Notes

Acknowledgments

The collection of cancer incidence data used in this study was supported by the California Department of Health Services (CADHS) as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institutes (NCI) Surveillance, Epidemiology and End Results Program under contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute (PHI); and the Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the PHI. The ideas and opinions expressed herein are those of the authors and endorsement by the CADHS, the NCI, and the CDC or their contractors and subcontractors is not intended nor should be inferred.

Disclosure

All authors have no conflicts to report.

References

  1. 1.
    Kiwit JC, Floeth FW, Bock WJ (1996) Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery. Zentralbl Neurochir 57:76–88PubMedGoogle Scholar
  2. 2.
    Ries LAG, Melbert D, Krapcho M, et al. (2007) SEER Cancer Statistics Review, 1975–2004. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2004/
  3. 3.
    Fritz A, Jack A, Parkin DM, et al. (2000) International Classification of Disease for Oncology. In: World Health Organization: WHO Library Cataloguing-in-Publication Data, 3rd edn. World Health Organization, Geneva. ISBN 92 4 154534 8 (NLM Classification: QZ 15)Google Scholar
  4. 4.
    Kleihues P, Louis DN, Scheithauer BW et al (2006) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225 discussion 226–229Google Scholar
  5. 5.
    Berry G, Kitchin RM, Mock PA (1991) A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 10:749–755PubMedCrossRefGoogle Scholar
  6. 6.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  7. 7.
    Chamberlain MC (2006) Treatment options for glioblastoma. Neurosurg Focus 20:E2CrossRefGoogle Scholar
  8. 8.
    Nomiya T, Nemoto K, Kumabe T et al (2007) Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg 106:575–581PubMedCrossRefGoogle Scholar
  9. 9.
    Tseng MY, Tseng JH (2005) Survival analysis for adult glioma in England and Wales. J Formos Med Assoc 104:341–348PubMedGoogle Scholar
  10. 10.
    Kayama T, Kumabe T, Tominaga T et al (1996) Prognostic value of complete response after the initial treatment for malignant astrocytoma. Neurol Res 18:321–324PubMedGoogle Scholar
  11. 11.
    Lin CL, Lieu AS, Lee KS et al (2003) The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol 60:402–406 discussion 406PubMedCrossRefGoogle Scholar
  12. 12.
    Krex D, Klink B, Hartmann C et al (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596–2606PubMedCrossRefGoogle Scholar
  13. 13.
    Davis FG, McCarthy BJ, Freels S et al (1999) The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 85:485–491PubMedCrossRefGoogle Scholar
  14. 14.
    Kraus JA, Wenghoefer M, Schmidt MC et al (2000) Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol 247:455–460PubMedCrossRefGoogle Scholar
  15. 15.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  16. 16.
    Polley M-YC, Lamborn KR, Chang SM et al (2011) Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol 29:4175–4180PubMedCrossRefGoogle Scholar
  17. 17.
    Laws ER, Parney IF, Huang W et al (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J Neurosurg 99:467–473PubMedCrossRefGoogle Scholar
  18. 18.
    Salminen E, Nuutinen JM, Huhtala S (1996) Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 32A:1918–1923PubMedCrossRefGoogle Scholar
  19. 19.
    Ramnarayan R, Dodd S, Das K et al (2007) Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter. J Neurol Sci 260:49–56PubMedCrossRefGoogle Scholar
  20. 20.
    Surawicz TS, Davis F, Freels S et al (1998) Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40:151–160PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Denice D. Tsao-Wei
    • 1
  • Jia Hu
    • 1
  • Susan G. Groshen
    • 1
  • Marc C. Chamberlain
    • 2
    Email author
  1. 1.Department of Preventive MedicineKeck School of Medicine, University of Southern CaliforniaLos AngelesUSA
  2. 2.Seattle Cancer Care Alliance, Fred Hutchinson Research Cancer Center, University of WashingtonSeattleUSA

Personalised recommendations